JAMA:Vericiguat 对射血分数保持的心力衰竭活动能力的影响

2020-10-21 MedSci原创 MedSci原创

对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分

射血分数保持的心力衰竭(HFpEF)患者具有较高的死亡率、住院率风险、以及功能和生活质量下降的风险。近日研究人员考察了口服可溶性鸟苷酸环化酶刺激剂Vericiguat治疗对HFpEF患者对堪萨斯心肌病问卷(KCCQ)活动受限评分(PLS)的影响。
 
在这项2b期随机、双盲、安慰剂对照、多中心试验中,789例慢性HFpEF患者参与,其左室射血分数在45%或更高,纽约心脏病协会症状评估为II-III级,最近一次失代偿后6个月内(HF住院治疗或未住院的静脉利尿剂治疗)出现利钠肽升高。患者随机接受Vericiguat 15 mg(n=264)、10 mg(n=263)或安慰剂(n=262)。研究的主要终点为治疗24周后KCCQ-PLS(范围0-100;较高值表示功能更好)变化。次要结果是从基线到24周的6分钟步行距离。
 
789名患者中,平均年龄为72.7岁,385名(49%)为女性,平均EF为56%;N-端前利钠肽平均水平为1403pg/mL,761名(96.5%)患者完成了试验。15 mg/d vericiguat、10 mg/d vericiguat和安慰剂组的基线检查和24周KCCQ PLS平均值分别为60.0和68.3,57.3和69.0,59.0和67.1,最小二乘平均变化分别为5.5、6.4和6.9。15mg/d vericiguat组与安慰剂组之间得最小二乘平均差为-1.5,10mg/d vericiguat组与安慰剂组得分之间的最小二乘平均差为-0.5。
在15mg/d vericiguat、10mg/d vericiguat和安慰剂组中,基线和24周6分钟步行距离分别为295.0m、311.8m、292.1m和318.3m、295.8m、311.4m,最小二乘平均变化分别为5.0m、8.7m和10.5m。15mg/d vericiguat组和安慰剂组之间的最小二乘平均差为-5.5m,10mg/d vericiguat组和安慰剂组之间的最小二乘平均差为-1.8m。在15mg/d vericiguat组中,出现症状性低血压的患者比例为6.4%,10mg/d vericiguat组为4.2%,安慰剂组为3.4%;晕厥患者比例分别为1.5%、0.8%和0.4%。
 
研究认为,对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分。
 
原始出处
 
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=894760, encodeId=f5b9894e60d8, content=在15mg/d vericiguat组中,出现症状性低血压的患者比例为6.4%,10mg/d vericiguat组为4.2%,安慰剂组为3.4%;晕厥患者比例分别为1.5%、0.8%和0.4%。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 10:50:19 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457417, encodeId=c587145e417b7, content=<a href='/topic/show?id=769a183858a' target=_blank style='color:#2F92EE;'>#Vericiguat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18385, encryptionId=769a183858a, topicName=Vericiguat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fff15924946, createdName=zhangjiqing, createdTime=Fri Oct 23 10:25:22 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893780, encodeId=6868893e80ea, content=对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Oct 22 16:47:05 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893625, encodeId=838a893625f6, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42045425563, createdName=飘雪1, createdTime=Wed Oct 21 22:52:39 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036314, encodeId=9d77103631423, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Oct 21 22:25:22 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2020-10-27 Lexi

    在15mg/d vericiguat组中,出现症状性低血压的患者比例为6.4%,10mg/d vericiguat组为4.2%,安慰剂组为3.4%;晕厥患者比例分别为1.5%、0.8%和0.4%。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=894760, encodeId=f5b9894e60d8, content=在15mg/d vericiguat组中,出现症状性低血压的患者比例为6.4%,10mg/d vericiguat组为4.2%,安慰剂组为3.4%;晕厥患者比例分别为1.5%、0.8%和0.4%。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 10:50:19 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457417, encodeId=c587145e417b7, content=<a href='/topic/show?id=769a183858a' target=_blank style='color:#2F92EE;'>#Vericiguat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18385, encryptionId=769a183858a, topicName=Vericiguat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fff15924946, createdName=zhangjiqing, createdTime=Fri Oct 23 10:25:22 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893780, encodeId=6868893e80ea, content=对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Oct 22 16:47:05 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893625, encodeId=838a893625f6, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42045425563, createdName=飘雪1, createdTime=Wed Oct 21 22:52:39 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036314, encodeId=9d77103631423, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Oct 21 22:25:22 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=894760, encodeId=f5b9894e60d8, content=在15mg/d vericiguat组中,出现症状性低血压的患者比例为6.4%,10mg/d vericiguat组为4.2%,安慰剂组为3.4%;晕厥患者比例分别为1.5%、0.8%和0.4%。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 10:50:19 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457417, encodeId=c587145e417b7, content=<a href='/topic/show?id=769a183858a' target=_blank style='color:#2F92EE;'>#Vericiguat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18385, encryptionId=769a183858a, topicName=Vericiguat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fff15924946, createdName=zhangjiqing, createdTime=Fri Oct 23 10:25:22 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893780, encodeId=6868893e80ea, content=对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Oct 22 16:47:05 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893625, encodeId=838a893625f6, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42045425563, createdName=飘雪1, createdTime=Wed Oct 21 22:52:39 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036314, encodeId=9d77103631423, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Oct 21 22:25:22 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2020-10-22 咻凡

    对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=894760, encodeId=f5b9894e60d8, content=在15mg/d vericiguat组中,出现症状性低血压的患者比例为6.4%,10mg/d vericiguat组为4.2%,安慰剂组为3.4%;晕厥患者比例分别为1.5%、0.8%和0.4%。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 10:50:19 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457417, encodeId=c587145e417b7, content=<a href='/topic/show?id=769a183858a' target=_blank style='color:#2F92EE;'>#Vericiguat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18385, encryptionId=769a183858a, topicName=Vericiguat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fff15924946, createdName=zhangjiqing, createdTime=Fri Oct 23 10:25:22 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893780, encodeId=6868893e80ea, content=对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Oct 22 16:47:05 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893625, encodeId=838a893625f6, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42045425563, createdName=飘雪1, createdTime=Wed Oct 21 22:52:39 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036314, encodeId=9d77103631423, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Oct 21 22:25:22 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2020-10-21 飘雪1

    好好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=894760, encodeId=f5b9894e60d8, content=在15mg/d vericiguat组中,出现症状性低血压的患者比例为6.4%,10mg/d vericiguat组为4.2%,安慰剂组为3.4%;晕厥患者比例分别为1.5%、0.8%和0.4%。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 10:50:19 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457417, encodeId=c587145e417b7, content=<a href='/topic/show?id=769a183858a' target=_blank style='color:#2F92EE;'>#Vericiguat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18385, encryptionId=769a183858a, topicName=Vericiguat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fff15924946, createdName=zhangjiqing, createdTime=Fri Oct 23 10:25:22 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893780, encodeId=6868893e80ea, content=对于射血分数保持的心力衰竭并伴有近期失代偿的患者中,与安慰剂相比,15mg/d或10mg/d的Vericiguat 治疗不能改善患者KCCQ活动受限评分, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Oct 22 16:47:05 CST 2020, time=2020-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893625, encodeId=838a893625f6, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42045425563, createdName=飘雪1, createdTime=Wed Oct 21 22:52:39 CST 2020, time=2020-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036314, encodeId=9d77103631423, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Oct 21 22:25:22 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2020-10-21 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Circulation:血浆蛋白质组学联合单细胞转录组学“排序”心梗后心衰标志物

心力衰竭(HF)是急性心肌梗死(MI)的最常见的远期并发症。了解与MI后HF相关的血浆蛋白及其基因表达可能会为发现生物标志物和药物靶标确定新的候选对象。

Lancet:SGLT2抑制剂对射血分数降低的心衰患者各类预后的影响

DAPA-HF(评估达格列净)和EMPEROR-Reduced (评估恩帕列净)试验都表明,钠-葡萄糖共转运体-2(SGLT2)抑制剂可降低射血分数降低(HFrEF)的心衰患者的心血管死亡或因心衰住院

Circulation:依帕列净治疗心力衰竭:利尿和心肾效应

钠-葡萄糖共转运体-2抑制剂可改善心力衰竭(心衰)的相关预后。然而,其机制尚不清楚,但利尿剂的特性可能起到一定作用。传统的利尿剂(如速尿)可诱导大量神经激素激活,导致经常出现有限的血管内容量改善。然而

Circulation:血管紧张素-脑啡肽酶抑制对心衰患者肾脏预后的影响

在心力衰竭(心衰)患者中,慢性肾脏疾病很常见。本研究评估了在PARAGON-HF试验中登记的射血分数保留的心衰患者中血管紧张素/脑啡肽酶抑制对肾脏的影响。

Circulation:基础利尿剂应用对达格列净治疗心衰时的疗效的影响

研究表明,钠葡萄糖共转运体2抑制剂达格列净降低了射血分数降低的心衰患者的心衰恶化和死亡风险。本研究拟评估达格列净与基础利尿剂治疗和达格列净对利尿剂剂量的影响。

JAMA:Praliciguat对保留射血分数的心力衰竭患者峰值摄氧量的影响

对于保留射血分数的心力衰竭患者,可溶性鸟苷酸环化酶刺激剂Praliciguat不能改善患者峰值摄氧量